1Marston BJ,Plouffe JF,File TM Jr.Incidence of community-acquired pneumonia requiring hospitalization:results of a population-based active surveillance study in Ohio.The community-based pneumonia incidence study group.Arch Intern Med,1997,157:1709-1718.
2Granton JT,Grossman RF.Community-acquired pneumonia in the elderly patient:clinical features,epidemiology,and treatment.Clin Chest Med,1993,14:537-553.
4Metlay JP,Schulz R,Li YH.Influence of age on symptoms at presentation in patients with community-acquired pneumonia.Arch Intern Med,1997,157:1453-1459.
6Riquelme R,Torres A,Ebiary M.Communityacquired pneumonia in the elderly.Clinical and nutritional aspects.Am J Respir Crit Care Med,1997,156:1908-1914.
7Riquelme R,Torres A,El-Ehiary M.Community-acquired pneumonia in the elderly:a multivariate analysis of risk and prognostic factors.Am J Respir Crit Care Med,1996,154:1450-1455.
8Waterer GW,Kessler LA,Wunderink RG.Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia.Chest,2006,130:11-15.
9Niederman MS,Brito V.Pneumonia in the older patient.Clin Chest Med,2007,28:751-771.
10Houek PM,MacLehose RF,Niederman MS,et al.Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states:1993,1995,and 1997.Chest,2001,119:1420-1426.
3Ramirez J A, Mgayen T.Treating community-acqured pneumonia with once- daily gatifloxacin VS twice-daily clarithromycin. J Respir Dis, 1999, 20:s60-69.
4Forrest A, Nix DE,Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother, 1993, 37:1073-1081
5Lode H, Borner K, Koeppe P. Pharmacodynamics of fluoroquinolones. Clin Infect Dis , 1998, 27:33-39.
6Dalnoff A. Pharmacodymics of fluoquinolones. J Antimicrob Chemother, 1999, 43:51-59.
7Ruiz-Gonzalez A, Falguera M,Nogues A, et al. Is streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia.Am J Med, 1999, 106:385-390.
8Niederman MS, Mandell LA, Anzueto A, et al.Guidelines for the management of adults with community-acquired pneumonia.Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med, 2001,163:1730-1754.
9Davies BI, Maesen FP. Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity. J Antimicrob Chemother, 1999, 43 Supple C:83-90.
10DeAbate CA, Russell M, et al. Safety and efficacy if oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbations of chronic bronchitis. Respir Care, 1999, 42:206-213.
8Rosbolt MB,Sterling ES,Fahy BG.The utility of the clinical pulmonary infection score[J].J Intensive Care Med,2009,24(1):26-34.
9Luna CM,Blanzaco D,Niederman MS,et al.Resolution of ventilator-associated pneumonia:prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome[J].Crit Care Med,2003,31(3):676-682.
10Nguyen HB, Knoblich BP, et al. Early lactate clearance is associated with improved outcome in severe sepsis and septic shock [ J ]. Crit Care Med ,2004,32 ( 8 ) : 1637 - 1642.
